In vitro and in vivo activities of amikacin, cefepime, amikacin plus cefepime, and imipenem against an SHV-5 extended-spectrum β-lactamase-producing Klebsiella pneumoniae strain

Antimicrobial Agents and Chemotherapy

Volumn 45, Issue 4, 2001, Pages 1287-1291

  Szabo D ^a   Mathe A ^a   Filetoth Z ^a   Anderlik, P ^a   Rokusz L ^a   Rozgonyi, F ^a  

^a SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; BETA LACTAMASE; CEFEPIME; CISPLATIN; IMIPENEM;

ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; COLONY FORMING UNIT; KLEBSIELLA PNEUMONIAE; NONHUMAN; OUTCOMES RESEARCH; PRIORITY JOURNAL; STATISTICAL ANALYSIS;

AMIKACIN; ANIMALS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; CEPHALOSPORINS; DRUG THERAPY, COMBINATION; IMIPENEM; KINETICS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MICE; MICROBIAL SENSITIVITY TESTS; SURVIVAL ANALYSIS;

EID: 0035086683     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.45.4.1287-1291.2001     Document Type: Article

References (30)

1. Assays for antimicrobial agents in body fluids
2. Lack of pharmacokinetic interaction between cefepime and amikacin in humans
3. Fluctuation of the volume of distribution of amikacin and its effect on once-daily dosage and clearance in a seriously ill patient
4. rd generation cephalosporins during nosocomial outbreak of multiresistant Klebsiella pneumoniae
5. Ceftriaxone-sulbactam combination in rabbit endocarditis caused by a strain of Klebsiella pneumoniae producing extended-broad-spectrum TEM-3 β-lactamase
6. Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections
7. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins
8. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men
9. Aminoglycoside dosing regimen and pharmacokinetic parameters in the guinea pig
10. Steady-state pharmacokinetics of imipenem in febrile neutropenic cancer patients
11. Factors affecting duration of in-vivo postantibiotic effect for aminoglycosides against Gram-negative bacilli
12. Do we need fourth-generation cephalosporins?
13. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome
14. More extended-spectrum β-lactamases
15. In vitro activities of various β-lactam antimicrobial agents against clinical isolates of Escherichia coli and Klebsiella spp. resistant to oxyimino cephalosporins
16. Pharmacokinetics of cefepime in patients with respiratory tract infections
17. Antimicrobial combinations
18. A comparative study of uranyl nitrate and cisplatin-induced renal failure in rat
19. Comparison of amikacin dosing regimens in neutropenic guinea pigs with Escherichia coli infection
20. Piperacillin, tazobactam, and gentamicin alone or combined in an endocarditis model of infection by a TEM-3-producing strain of Klebsiella pneumoniae or its susceptible variant
21. Clinical strategies for serious infection: A North American perspective
22. Postantibiotic effects of imipenem, norfloxacin, and amikacin in vitro and in vivo
23. In vivo efficacies of β-lactam-β-lactamase inhibitor combinations against a TEM-26-producing strain of Klebsiella pneumoniae
24. Susceptibility to new beta-lactams of enterobacterial extended-spectrum beta-lactamase (ESBL) producers and penicillin-resistant Streptococcus pneumoniae in Mexico
25. Molecular epidemiology of a cluster of cases due to Klebsiella pneumoniae producing SHV-5 extended-spectrum β-lactamase in the premature intensive care unit of a Hungarian hospital
26. Efficacies of piperacillin-tazobactam and cefepime in rats with experimental intra-abdominal abscesses due to an extended-spectrum β-lactamase-producing strain of Klebsiella pneumoniae
27. Pharmacokinetics of antibiotics in critically ill patients
28. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model
29. Performance of a fluorescence polarization immunoassay system evaluated by therapeutic monitoring of four drugs